Genetics

Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, today announced financial results and provided a business update for the year ended December 31, 2017. As quoted in the press release: David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp., stated, “2017 was a very exciting year for Avalon as we laid …

Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, today announced financial results and provided a business update for the year ended December 31, 2017.

As quoted in the press release:

David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp., stated, “2017 was a very exciting year for Avalon as we laid the foundation in our efforts to become a significant player in the cell therapy and regenerative medicine markets. I am pleased to report the acquisition of the executive center property in Freehold, NJ, which houses our headquarters. This new facility is an important step in our overall strategy to build a global network of healthcare facilities that will both generate immediate cash flow and provide a network to support the roll-out of our planned cell therapies and related services. As a next step in our growth strategy, we acquired a controlling position in a Beijing exosome technology company, GenExosome Technologies Inc. (GenExosome), to pursue the global advancement of exosome technology for diagnosis and treatment of diseases. GenExosome’s Exosome Isolation Systems were designed for use by researchers for biomarker discovery and clinical diagnostic development, as well as the advancement of targeted therapies.”

Click here to read the full press release.

MARKETS

Markets
TSX19625.72-67.20
TSXV653.22+7.18
DOW32754.81-43.59
S&P 5004136.60+17.97
NASD12486.45+117.48
ASX6993.00+47.80

COMMODITIES

Commodities
Gold1779.27+7.33
Silver20.27-0.06
Copper3.52-0.03
Palladium2080.50-116.50
Platinum914.00+4.00
Oil94.72+0.83
Heating Oil3.40-0.04
Natural Gas7.84-0.45

DOWNLOAD FREE REPORTS

×